NexgenRx Inc.
NXG.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.56M | 11.55M | 11.33M | 10.81M | 10.39M |
| Total Other Revenue | 459.70K | 421.20K | 447.60K | 450.50K | 437.20K |
| Total Revenue | 12.02M | 11.97M | 11.78M | 11.26M | 10.82M |
| Cost of Revenue | 2.44M | 2.39M | 2.59M | 2.41M | 2.31M |
| Gross Profit | 9.58M | 9.58M | 9.19M | 8.85M | 8.51M |
| SG&A Expenses | 7.77M | 7.78M | 7.90M | 7.75M | 7.46M |
| Depreciation & Amortization | 907.00K | 924.70K | 933.30K | 946.30K | 961.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.12M | 11.10M | 11.43M | 11.11M | 10.73M |
| Operating Income | 900.40K | 873.00K | 355.20K | 148.00K | 92.50K |
| Income Before Tax | 774.40K | 747.90K | 208.40K | 2.30K | -27.70K |
| Income Tax Expenses | 294.00K | 292.90K | 18.60K | 19.50K | 19.20K |
| Earnings from Continuing Operations | 0.48 | 0.45 | 0.19 | -0.02 | -0.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 480.30K | 454.90K | 189.70K | -17.20K | -46.90K |
| EBIT | 900.40K | 873.00K | 355.20K | 148.00K | 92.50K |
| EBITDA | 1.60M | 1.61M | 1.28M | 1.08M | 1.04M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 283.59M | 283.39M | 283.46M | 282.91M | 282.32M |
| Average Diluted Shares Outstanding | 300.39M | 296.39M | 296.46M | 295.61M | 294.72M |
| Dividend Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | 83.97% | 88.99% | 337.22% | -3,721.51% | -1,423.67% |